TRT And Sleep Apnea: Risks, Screening, And Management

TRT and sleep apnea are linked in both directions. Obstructive sleep apnea (OSA) disrupts the hormonal signaling required for testosterone production, while testosterone replacement therapy may worsen breathing disturbances during sleep in some men. The Endocrine Society's 2018 clinical practice guideline recommends against starting TRT in men with untreated severe OSA (Bhasin et al., 2018). That doesn't mean men with both conditions can't receive treatment. It means the treatment sequence, monitoring cadence, and hematocrit management all matter. Marek Health providers evaluate both conditions as part of the diagnostic workup before prescribing testosterone therapy.

TRT and sleep apnea is a clinical pairing where testosterone replacement therapy and obstructive sleep apnea interact through shared effects on red blood cell production, oxygen delivery, and cardiovascular risk. Proper screening and monitoring can support safer treatment of both.

How does sleep apnea affect testosterone levels?

Testosterone secretion follows a circadian rhythm tied to sleep architecture. The largest pulses of gonadotropin-releasing hormone (GnRH) occur during REM sleep, and disrupted REM reduces the downstream signal to produce testosterone. Men with OSA experience repeated apneic episodes that fragment sleep and prevent sustained REM stages.

A review published in the World Journal of Men's Health found that OSA in middle-aged men is associated with decreased testosterone secretion independent of obesity and aging (Kim and Cho, 2019). The association isn't minor. Severe OSA correlates with greater testosterone reductions than mild or moderate forms, and meta-analytic data supports this dose-response pattern across study populations.

Body composition plays a role too. OSA increases visceral fat accumulation, which raises aromatase activity and converts more testosterone to estradiol. This secondary mechanism compounds the direct hormonal suppression from sleep fragmentation. 

Men who notice symptoms of low testosterone alongside heavy snoring, morning headaches, or daytime fatigue should consider that the two conditions may be feeding each other.

Can TRT worsen sleep apnea?

The evidence is split between observational and interventional data, and the answer depends on study design.

A retrospective cohort study using the TRICARE military health system database found that men on TRT had a higher two-year OSA diagnosis rate (16.5%) compared to controls (12.7%) (Cole et al., 2018). This data used administrative ICD codes, not polysomnography, so it reflects diagnostic coding rather than confirmed airway measurements.

On the other hand, a meta-analysis of interventional studies found that testosterone therapy did not worsen objective measures of sleep apnea in controlled settings (Yassin et al., 2022). Some participants showed no change, and a subset showed mild improvement.

The mechanisms by which TRT could aggravate OSA are well described, even if the clinical magnitude is debated. Testosterone may increase upper airway resistance by altering neuromuscular tone, change the ventilatory response to hypoxia and hypercapnia, and shift metabolic oxygen demands during sleep (Kim and Cho, 2019). These effects appear to be more pronounced in men with pre-existing anatomical risk factors for airway collapse, including higher BMI and larger neck circumference.

The clinical takeaway: current evidence doesn't establish that TRT causes OSA, but it may unmask or mildly worsen it in predisposed men. This makes pre-treatment screening and ongoing monitoring part of responsible prescribing.

Polycythemia: the risk where TRT and sleep apnea overlap

Polycythemia (also called erythrocytosis) is the most clinically relevant overlap between TRT and sleep apnea. Both conditions independently raise red blood cell production through different pathways, and the combined effect can push hematocrit to clinically concerning levels.

OSA triggers polycythemia through intermittent hypoxia. When blood oxygen drops repeatedly during apneic episodes, the kidneys increase erythropoietin (EPO) secretion. EPO signals bone marrow to produce more red blood cells in an attempt to improve oxygen-carrying capacity.

TRT also stimulates erythropoiesis. Testosterone directly increases red blood cell production through its effects on EPO and iron metabolism. For most men, this produces a modest, manageable rise in hematocrit. But when both drivers are active simultaneously, the rise can be additive.

A single-center study of 474 hypogonadal men on TRT found that 13.1% developed polycythemia (median hematocrit 53.6%). Of the men with polycythemia, 37 of 62 (approximately 60%) also had an OSA diagnosis. After adjusting for age, BMI, and peak testosterone levels, OSA remained an independent predictor of polycythemia with an odds ratio of 2.09 (Lundy et al., 2020). BMI was the only other risk factor with a strong independent association.

When hematocrit rises above 54%, blood viscosity increases enough to raise the risk of stroke, venous thromboembolism, and cardiovascular events. Multiple clinical guidelines flag 54% as the threshold requiring dose reduction or therapeutic phlebotomy (Bhasin et al., 2018). For men with concurrent OSA, some providers consider acting earlier, at the 50-52% range, especially if OSA remains untreated. This lower threshold reflects clinical judgment rather than a specific guideline recommendation.

The following table shows how TRT and OSA interact across clinical risk factors:

Who should be screened before starting TRT?

The Endocrine Society guideline recommends against initiating TRT in untreated severe OSA (Bhasin et al., 2018). The AUA testosterone deficiency guideline takes a similar position, emphasizing that sleep-disordered breathing should be assessed as part of the pre-treatment evaluation.

Clinical indicators that warrant a sleep study before starting testosterone therapy include habitual snoring reported by a bed partner, witnessed apneic episodes, morning headaches, excessive daytime sleepiness despite adequate time in bed, BMI above 30, and neck circumference above 17 inches. Home sleep apnea tests (HSATs) can screen for moderate-to-severe OSA without an overnight lab stay.

Men already on TRT who develop symptoms of sleep disruption, unexplained rises in hematocrit, or new-onset hypertension should also be evaluated. The Lundy et al. data showed that OSA was often diagnosed after polycythemia appeared during TRT monitoring, not before therapy started.

Managing TRT in men with sleep apnea

A confirmed OSA diagnosis doesn't necessarily disqualify a man from TRT. It changes the management protocol.

Treating sleep apnea first

Continuous positive airway pressure (CPAP) is the first-line treatment for moderate-to-severe OSA. Mandibular advancement devices and positional therapy are alternatives for mild cases. Treating OSA before or at the same time as initiating TRT may reduce the hypoxia-driven EPO stimulus and lower the baseline risk for polycythemia.

Weight reduction, when applicable, addresses one of the strongest shared risk factors. OSA prevalence increases with BMI, and excess visceral fat suppresses testosterone through aromatase-mediated estradiol conversion. Treating the metabolic driver can benefit both conditions simultaneously.

Hematocrit monitoring during therapy

Providers should check hematocrit at baseline, 3 months after starting TRT, and every 6-12 months thereafter. For men with concurrent OSA, more frequent monitoring (every 8-12 weeks in the first year) may be warranted. This interval reflects clinical judgment informed by the Lundy et al. findings, not a specific guideline recommendation. Staying current with hematocrit management protocols is part of safe, medically supervised testosterone therapy.

If hematocrit exceeds 54%, guidelines recommend dose reduction, a switch to a different testosterone formulation, temporary suspension of TRT, or therapeutic phlebotomy (Bhasin et al., 2018). Phlebotomy (a standard blood draw of approximately one unit) rapidly lowers hematocrit and is a routine intervention in clinical practice.

Dose and formulation adjustments

Injectable testosterone (cypionate and enanthate) tends to produce sharper peaks in serum testosterone, which can drive more erythropoiesis compared to transdermal gels or patches. Men with OSA-related polycythemia risk may benefit from lower peak formulations, more frequent smaller injections, or transdermal delivery to keep testosterone levels more stable.

Monitoring should also include blood pressure at each visit, given the February 2025 FDA labeling update that added a blood pressure warning to all testosterone products based on the TRAVERSE trial's ambulatory blood pressure monitoring data (FDA, 2025).

Does treating sleep apnea improve testosterone?

Some studies report modest testosterone increases after CPAP therapy, but the evidence isn't consistent enough to call CPAP a testosterone treatment.

The improvements seen in studies may reflect better sleep architecture (restoring the REM-dependent GnRH pulses) and weight loss associated with improved energy levels and daytime function. OSA treatment may also reduce cortisol, which could indirectly support testosterone production.

What is consistent: men who treat their OSA before starting TRT may respond better to testosterone therapy and experience fewer hematocrit-related complications. Treating the sleep disorder removes one of the two drivers of polycythemia. The TRT-related hematocrit rise becomes more predictable and manageable.

For men diagnosed with hypogonadism, addressing both conditions together, rather than treating either in isolation, is associated with safer and more stable outcomes.

What the TRAVERSE trial means for TRT safety

The TRAVERSE trial enrolled 5,246 men aged 45-80 with hypogonadism and pre-existing cardiovascular risk. The primary endpoint (major adverse cardiac events) was 7.0% in the testosterone group versus 7.3% in the placebo group, meeting the noninferiority threshold (Lincoff et al., 2023). This data led the FDA to remove the prior boxed cardiovascular warning from testosterone labeling in February 2025.

TRAVERSE also found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group. These secondary signals matter for men with OSA, whose cardiovascular system already operates under strain from intermittent hypoxia. The trial reinforces that TRT in higher-risk populations requires close monitoring, not blanket avoidance, and that safety depends on individualized patient selection and follow-up.

Fertility should also be discussed before starting TRT. Testosterone therapy suppresses spermatogenesis, and the degree and reversibility of this suppression varies between individuals. Providers may offer adjunctive therapies like hCG for men who wish to preserve fertility during treatment, though individual response varies.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does sleep apnea lower testosterone levels?

OSA is associated with reduced testosterone levels independent of age and BMI. The mechanism involves disrupted REM sleep, which is when the largest pulses of GnRH occur. Severe OSA correlates with greater testosterone reductions than mild or moderate forms.

Can TRT be started with a sleep apnea diagnosis?

The Endocrine Society recommends against initiating TRT in men with untreated severe OSA. Once OSA is being treated (with CPAP or another appropriate intervention), TRT can generally be initiated with proper monitoring. The decision depends on the severity of OSA, the treatment compliance, and the individual's overall cardiovascular risk profile.

How does TRT and sleep apnea together raise hematocrit?

OSA raises red blood cell production through hypoxia-driven EPO secretion. TRT independently stimulates erythropoiesis. When both are present, the effect is additive. In the Lundy et al. study, men with TRT and OSA had 2.09 times the odds of developing polycythemia compared to men on TRT without OSA.

What monitoring is needed during TRT for men with OSA?

Hematocrit should be checked at baseline, at 3 months, and every 6-12 months. Men with concurrent OSA may need checks every 8-12 weeks in the first year. Blood pressure monitoring is also required per the 2025 FDA labeling update. If hematocrit exceeds 54%, guidelines recommend dose reduction or therapeutic phlebotomy.

Does CPAP treatment improve testosterone levels?

Some studies show modest testosterone increases after CPAP therapy, but results aren't consistent across all populations. The more reliable benefit is indirect: treating OSA removes one driver of polycythemia, may reduce cortisol, and restores sleep architecture, all of which can support a better hormonal environment.

Is telehealth appropriate for TRT and sleep apnea management?

Telehealth evaluation is appropriate for both conditions, provided it includes lab confirmation (two early-morning testosterone draws plus a complete blood count including hematocrit) and a clinical evaluation by a licensed provider. Home sleep apnea tests can screen for OSA without an in-person lab stay. Testosterone is a Schedule III controlled substance prescribed only when medically appropriate, subject to state and federal telehealth rules through December 31, 2026.

References

• BJU Int. 2018;121(5):811-818

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• J Clin Endocrinol Metab. 2022;107(2):e463-e471

• J Sex Med. 2020;17(7):1297-1303

• N Engl J Med. 2023;389(2):107-117

• U.S. FDA. FDA Issues Class-Wide Labeling Changes for Testosterone Products. February 2025

• World J Mens Health. 2019;37(1):12-18